Abstract: A virucidal, spermicidal vaginal gel consisting essentially of povidone iodine having a povidone to iodine ratio of about 15:1 or higher containing from about one percent to about twenty percent low molecular weight povidone having a molecular weight of about 20 kd or lower, the gel having a viscosity such that a conical body drawn from a body of the same does not visibly slump at 37C. for a period of at least one minute and a method of preventing sexual transmission of disease and preventing pregnancy using the same are disclosed.

Abstract: A method of purifying platelet-bearing liquid by contacting the liquid to be purified with solid povidone-iodine to expose the liquid to I.sub.2 on such surface to kill pathogenic organisms therein and removing the liquid from contact with the solid povidone-iodine, and the use of the same in treating patients are disclosed.

Abstract: The treatment and preservation of blood, blood derivatives and other body tissues, fluids and cells with povidone-iodine and then quenching the oxidizing potential of iodine in the povidone iodine to kill pathogenic microbes without destroying the utility of the tissues, fluids and cells is disclosed.

Abstract: The invention provides a simple, safe and effective method for treating bone and making it suitable for transplantation comprising: (a) contacting said bone with a global decontaminating agent effective to inactivate bacteria, fungi, virus and parasites; (b) cleaning said bone; and (c) terminally decontaminating said cleaned bone by contacting it with a global decontaminating agent effective to inactivate bacteria, fungi, virus and parasites. The invention also provides a method of cleaning bone which can be used in step (b) of the method described above and comprises contacting the bone with detergent under high pressure washing conditions at elevated temperatures.

Abstract: Biologically competent non-pasteurized albumin wherein virus present in the source fluid has been inactivated with one or more of a class of compounds exemplified by glycyrrhizin, glycyrrhizinic acid or glycyrrhetinic acid glycoside, and analogous triterpenes, e.g. carbenoxolone and cicloxolone and their derivatives, and blood substitutes comprising such albumin and hemoglobin are disclosed.

Abstract: The treatment of blood plasma to inactivate or destroy infective viruses, such as the cytomegalovirus CMV, by mixing the plasma with an effective amount of glycyrrhizic triterpenoid compounds is disclosed. Detergents, glycerol or ethylene diamine tetraacetic acid can be added to augment the affect of the glycyrrhizic triterpenoid compounds.

Abstract: The treatment of blood or body fluid and body fluid samples to inactivate or destroy infective viruses, such as the cytomegalovirus, by mixing the sample with an effective amount of glycyrrhizic triterpenoid-detergent, glycyrrhizic triterpenoid-glycerol or glycyrrhizic triterpenoid-EDTA, combination followed by analysis or testing for diagnostic or other purposes is disclosed.

Abstract: A transfusion blood product container for the introduction of one or more blood products, such as whole blood, platelet concentrations, leukocyte concentrations, plasma, phasma derivatives, whole blood fractions, and combinations thereof, for transfusing the patient and an amount of one or more glycyrrhizic triterpenoid compounds sufficient to comprise from 0.05 to 10.0 wt/%, preferably from about 0.5 to about 3 wt/%, of the contents of the container when full of the blood product(s), sufficient to substantially inactivate viruses contained in the blood product introduced into said container is disclosed. One or more additional products are added to the glycyrrhizic triterpenoid compounds to produce a synergistic affect.

Abstract: The treatment of blood product to inactivate or destroy infective viruses found in animal fluids and tissues, such as the cytomegalovirus, by mixing the blood product with an effective amount of glycyrrhizic triterpenoid compounds in combination with albumin is disclosed.

Abstract: Nutrient, such as fetal calf serum, for tissue culture medium comprising serum and one or more glycyrrhizic triterpenoid compounds and delipidated albumin to inactivate BVD, CMV and other susceptible viruses and processes of protecting tissue cultures from viral infection are disclosed.

Abstract: An intravascular catheter comprising a cannula for insertion into a vascular system of a patient coated with hydrophilic polymer containing, in the polymer, an effective amount of polymyxin to prevent the growth of microorganisms is disclosed.

Abstract: Methods and compositions for treating infectious diseases comprising introducing such compositions, which consist essentially of one or more glycyrrhizie triterpenoid compounds, such as, for example, carbenoxolone, glycyrrhizin or cicloxolone, are disclosed. Therapy by inhalation is contemplated.

Abstract: Procedure for the preparation of a concentrate of prothrombinogenic compound.This procedure, in which, starting from a source of prothrombinogenic compound, an adsorption is followed by an elution, is characterized by the fact that a source of prothrombinogenic compound and a source of antithrombin III (or AT III) is placed in contact with an adsorbing agent capable of adsorbing both the prothrombinogenic compound and antithrombin III, and that the foregoing occurs in the presence of heparin, at least during the elution stage, and that elution is carried out with an elution agent capable of eluting the prothrombinogenic compound, the AT III and heparin at the same time.Application of the product obtained, notably to the treatment of blood coagulation difficulties.

Abstract: Products and materials used in the biomedical field are depyrogenated by prolonged contact with a solution or suspension of about 0.1% to about 10% by weight of a nonionic amphiphile selected from the group consisting of substances having the general formula RC.sub.6 H.sub.4 (OC.sub.2 H.sub.4).sub.n OH wherein R is octyl or nonyl and n is at least 3, followed by liquid phase separation of said amphiphile from the resulting depyrogenated product or material.

Abstract: An improved process for preparing factor VIII concentrate which comprises a first stage wherein fibrinogen is precipitated from a buffered plasma or plasma cryoprecipitate solution by the addition of a polyol and a second stage where factor VIII is precipitated from the resulting supernatant also by the addition of a polyol. The improvement in the first stage resides in adding the polyol in an amount of 1-3% and maintaining the temperature of the buffered solution between about 2.degree.-4.degree. C.

Abstract: Biological and pharmaceutical products which are contaminated with pyrogens are depyrogenated by prolonged contact with a solution or suspension of from about 0.25% to about 10% by weight of a non-denaturing amphiphile.

Abstract: Plasma, plasma derivatives and products thereof are subjected to prolonged contact with a solution or suspension of from about 0.25% to about 10% by weight of a non-denaturing amphiphile to cause irreversible destruction of endotoxins, destruction of thromboplastic-like coagulation activating substances and inactivation of hepatitis viruses (B and non-A, non-B).

Abstract: AHF and CIg yield and purity in cryoprecipitate concentrate are improved by suspending said cryoprecipitate concentrate in aqueous solution and then subjecting to a heat treatment step at a temperature of from about 45.degree. C. to about 56.degree. C. for a period of from about one minute to about sixty minutes to thereby selectively thermally precipitate the contaminating proteins without substantial loss or AHF of CIg activities and recovering the purified AHF on CIg from the precipitate of contaminating proteins.

Abstract: Polyethylene glycol or poly(oxyethylene)poly(oxypropylene) glycol block copolymers or mixtures thereof in a suitable buffer such as citrated saline, are added to blood plasma to preserve and protect blood coagulation factors and other proteins.

Abstract: A method for concentrating and purifying Factor VIII by selective cold precipitation in low ionic strength solution is disclosed.